Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Stock forecast & fair value
Kiniksa Pharmaceuticals International (KNSA) stock forecast and price target
Kiniksa Pharmaceuticals International (KNSA) trades at $93.86. 7 analysts' median price target is $102.00 (+9%), from $98.00 to $134.00.
Kiniksa Pharmaceuticals International's latest quarter
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for KNSA stock?
The median of 7 analysts' 12-month targets is $102.00, +9% from $93.86; the range is $98.00 to $134.00. The average rating is strong buy.
Does Kiniksa Pharmaceuticals International usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is KNSA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.